The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland ; volume:36 ; number:4 ; day:6 ; month:7 ; year:2022 ; pages:537-547 ; date:7.2022
BioDrugs ; 36, Heft 4 (6.7.2022), 537-547, 7.2022
- Classification
-
Wirtschaft
- Creator
-
Luukkanen, Saana V.
Tolonen, Hanna M.
Airaksinen, Marja
Saarukka, Laura S. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-022-00540-y
- URN
-
urn:nbn:de:101:1-2022090101360030283380
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Luukkanen, Saana V.
- Tolonen, Hanna M.
- Airaksinen, Marja
- Saarukka, Laura S. M.
- SpringerLink (Online service)
Other Objects (12)
Biosimilars – Biosimilars: ja, aber
Biosimilars
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Biosimilars : Handbuch
Understanding the market dynamics of biosimilars
Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Life science in the capital market : biosimilars
Pharmacovigilance Considerations for Biosimilars in the USA
Interchangeability of Biosimilars: Overcoming the Final Hurdles
Biosimilars – Biosimilars: ja, aber
Biosimilars
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Biosimilars : Handbuch
Understanding the market dynamics of biosimilars
Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Life science in the capital market : biosimilars
Pharmacovigilance Considerations for Biosimilars in the USA
Interchangeability of Biosimilars: Overcoming the Final Hurdles
Biosimilars – Biosimilars: ja, aber
Biosimilars
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Biosimilars : Handbuch
Understanding the market dynamics of biosimilars
Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Life science in the capital market : biosimilars
Pharmacovigilance Considerations for Biosimilars in the USA